Cloning of the Epo gene in the early 1980s allowed the development of erythropoiesis stimulating agents (ESAs) including recombinant human Epo (rHuEpo) as a treatment for anemia in multiple settings, offering an alternative to transfusion as a method of raising or maintaining hemoglobin levels in patients. Here, EPO is linked to anemia.